Tag Archives: Casper de Clercq of Norwest Venture Partners

Feb. 7, 2012 SVForum PWC

On Tuesday February 7, 2012 in Palo Alto at Pillsbury Winthrop, SVForum presented the SVForum Quarterly Venture Breakfast with Pillsbury Winthrop and PricewaterhouseCoopers. The topic was “2011 The Year In Review.” Allison Leopold Tilley of Pillsbury Winthrop moderated panelists Steve Bengston of PricewaterhouseCoopers, Casper de Clercq of Norwest Venture Partners, Steve Goldberg of Venrock and Ann Winblad of Hummer Winblad. They discussed the past year and prospects for the next.

Venture capital investments went up from $23 billion in 2010 to $26 billion in 2011. Fundraising went up from $10 billion in 2010 to $12 billion in 2011. This growth is seen as unsustainable when the top sectors of cleantech, biotech, and medical devices are vulnerable to scaling and regulatory issues. Despite the IPOs of LinkedIn and Pandora, the trend toward VC backed companies going public declined from 75 in 2010 to 50 in 2011. This does not help the unemployed if over ninety percent of job creation occurs after a company has an IPO. The Facebook IPO may generate more Silicon Valley angel investing, but such investment has not generated well paying jobs in the US.

According to the US Dept of Commerce and Wall Street Journal, multinationals over the past decade have cut 2.9 million jobs in the US and moved 2.4 overseas. One result is that over 80 percent of internet growth is overseas where more than 90 percent of the children under 15 live in emerging markets. One place the population may not be growing is in China, where the workforce will peak in 2015 and become the world’s largest economy by 2017 but be surpassed in population by India in 2020. Growth in Europe is unlikely considering their continuing instability as seen in Greece.

Despite more money going in, there are fewer exits. The current situation is unsustainable.

 

Copyright 2012 DJ Cline All rights reserved.

 

Jul. 26, 2011 SVForum PWC Biotech

On July 26, 2011 in Palo Alto, SVForum with Pillsbury Winthrop and PricewaterhouseCoopers held their Quarterly Venture Breakfast on Biotech. Tom Thomas of Pillsbury Winthrop moderated panelists Steve Bengston of PricewaterhouseCoopers, Casper de Clercq of Norwest Venture Partners, Jonathan MacQuitty of Abingworth Venture Capital and Eric Shiozaki of Apposite Capital.

Developing drugs can be a slower and uncertain process in America than launching in Europe. Despite that, venture capitalists are still plowing what looks like an unsustainable amount of early stage funding into biotech. Savvy investors look for later rounds after new drugs or devices pass FDA scrutiny, which has become a financial gauntlet for small startups. A growing number of clinical trials are taking place in emerging economies but less regulation means less reliable results. This outsourcing risks losing America’s ability to develop drugs domestically. It also is slowing and some cases stopping new products from reaching patients.

The exits are more likely a buyout from a big pharmaceutical company than an IPO. Many of the pharma giants are looking for something to replace their expiring patents next month. Investing in new life saving drugs is as risky as taking them.

Copyright 2011 DJ Cline All rights reserved.